Mayra Rivera Figueroa, MD
Hematology & Oncology · Rio Piedras, PRNPI 1619032893
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,456 of the $23,121 with a category attached, or 66.8%. 27 manufacturers reported payments, led by Merck at 38.4% of the total. Reporting peaked in 2019 at $8,255 and has fallen 77.1% since, to $1,887 in 2025.
Across 222 payments — averaging $104.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9K
- Johnson & Johnson$6K
- E.r. Squibb & Sons, L.L.C.$5K
- AstraZeneca$598
- AbbVie$530
- Eli Lilly Export S.A. Puerto Rico Branch$355
- plus $2K from 21 others
Across 80 payments — averaging $9024.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$559K
- E.r. Squibb & Sons, L.L.C.$88K
- AbbVie$71K
- Eli Lilly Export S.A. Puerto Rico Branch$5K
- Eli Lilly$156
What the payments were for
- Consulting fees$15,45667%
- Travel & lodging$1,5307%
- Food & beverage$5,35223%
- Education$7833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 39 | $8,882 |
| Johnson & Johnson(2 entities) | 23 | $5,578 |
| E.r. Squibb & Sons, L.L.C. | 27 | $4,913 |
| AstraZeneca | 21 | $598 |
| AbbVie | 20 | $530 |
| Eli Lilly Export S.A. Puerto Rico Branch | 18 | $355 |
| Sanofi | 11 | $350 |
| GSK | 8 | $209 |
| Rigel Pharmaceuticals, Inc. | 3 | $202 |
| Novartis | 8 | $193 |
| Incyte Corporation | 4 | $171 |
| Sanofi-aventis U.S. LLC | 2 | $170 |
| Amgen | 8 | $164 |
| Tempus AI, Inc | 6 | $145 |
| Lilly USA, LLC | 3 | $116 |
| Caris MPI, Inc. | 3 | $101 |
| PBG Puerto Rico LLC | 3 | $77 |
| Puma Biotechnology, Inc. | 3 | $75 |
| EMD Serono, Inc. | 2 | $51 |
| Exelixis Inc. | 2 | $41 |
| Foundation Medicine, Inc. | 1 | $40 |
| Genentech USA, Inc. | 2 | $38 |
| Sobi, Inc | 1 | $36 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Pharmaessentia USA Corporation | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,121 in reported general payments places this provider in the 75th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 39 | $602,732 |
| RevlimidLenalidomide | 25 | $403,957 |
| JakafiRuxolitinib Phosphate | 17 | $362,241 |
| XtandiEnzalutamide | 23 | $327,117 |
| TagrissoOsimertinib Mesylate | 11 | $183,560 |
| VenclextaVenetoclax | 19 | $144,231 |
| ZytigaAbiraterone Acetate | 12 | $129,312 |
| Lupron DepotLeuprolide Acetate | 13 | $58,622 |
| Abiraterone Acetate | 38 | $40,846 |
| Everolimus | 18 | $30,220 |
| EligardLeuprolide Acetate | 25 | $22,154 |
| EliquisApixaban | 16 | $10,192 |
| XareltoRivaroxaban | 13 | $7,485 |
| Anastrozole | 218 | $3,586 |
| Exemestane | 35 | $2,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $116 | $602,76650 claims |
| Incyte CorporationJakafi | $171 | $362,24117 claims |
| AbbVieVenclexta, Lupron Depot | $530 | $202,85332 claims |
| AstraZenecaTagrisso | $598 | $183,56011 claims |
| Johnson & JohnsonZytiga, Xarelto | $5,578 | $136,79625 claims |
| PfizerEliquis | $14 | $10,19216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Rio Piedras
- Armando GarciaRio Piedras$39K
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Joel Lopez-FigueroaHumacao$163K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Carlos Mendez SerranoCaguas$91K
- Santa MerleMoca$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.